Vertex Pharmaceuticals Aktie
| 471,81USD | 9,70USD | 2,10% |
WKN: 882807 / ISIN: US92532F1003
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 3 400 | 3 900 | 4 800 | 5 400 | 6 100 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,83 | 1,95 | 1,82 | 1,82 | 1,80 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 8 133 | 9 561 | 13 235 | 14 144 | 9 596 |
| Summe Anlagevermögen | 3 618 | 3 872 | 4 916 | 8 942 | 13 494 |
| Summe Aktiva | 11 752 | 13 433 | 18 151 | 23 086 | 23 091 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 3 065 | 3 333 | 4 238 | 5 506 | 6 681 |
| Summe Eigenkapital | 8 687 | 10 100 | 13 913 | 17 580 | 16 410 |
| Summe Passiva | 11 752 | 13 433 | 18 151 | 23 086 | 23 091 |
Adresse
| 50 Northern Avenue, 02210 Boston | |
| Telefon | +1 (617) 341-6100 |
| Internet | http://www.vrtx.com |
Management
|
Alan M. Garber
Independent Director |
|
Amit K. Sachdev
Chief Patient & External Affairs Officer |
|
Bruce I. Sachs
Lead Independent Director |
|
Carmen Bozic
Chief Medical Officer & EVP-Medical Affairs |
|
Catherine Rutten
Vice President-International & Government Affairs |
|
Charles F. Wagner
Chief Financial Officer & Executive Vice President |
|
David Matthew Altshuler
Chief Scientific Officer & EVP-Global Research |
|
Diana L. McKenzie
Independent Director |
|
Edward Morrow Atkinson
Chief Technical Operations Officer & Executive VP |
|
Jeffrey M. Leiden
Executive Chairman |
|
Jennifer Schneider
Independent Director |
|
Jonathan Prim Biller
Chief Legal Officer & Executive Vice President |
|
Joy Liu
Secretary, Senior Vice President & General Counsel |
|
Kristen C. Ambrose
Chief Accounting Officer & Senior Vice President |
|
Lloyd A. Carney
Independent Director |
|
Ludovic Fenaux
Senior VP-International Commercial Operations |
|
Michel Lagarde
Independent Director |
|
Nancy A. Thornberry
Independent Director |
|
Nia Tatsis
Chief Regulatory & Quality Officer, Executive VP |
|
Nicole A. Gabreski
Associate Director-External Innovation |
|
Reshma Kewalramani
President, Chief Executive Officer & Director |
|
Sangeeta N. Bhatia
Independent Director |
|
Sean Daughtry
Senior Director-Analytical Sciences & Technology |
|
Stephanie Franklin
Chief Human Resources Officer & Senior VP |
|
Stuart A. Arbuckle
Chief Operating Officer & Executive Vice President |
|
Suketu P. Upadhyay
Independent Director |
|
Susie Lisa
Senior Vice President-Investor Relations |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.